Nautilus Biotechnology, Inc.

The momentum for this stock is not very good. Nautilus Biotechnology, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Nautilus Biotechnology, Inc..

News

Nautilus Biotechnology, Inc.'s (NASDAQ:NAUT) Top Key Executive Parag Mallick is the most upbeat insider, and their holdings increased by 11% last week

Simply Wall St Key Insights Insiders appear to have a vested interest in Nautilus Biotechnology's growth, as seen by their sizeable...\n more…

Nautilus Biotechnology (NASDAQ:NAUT) Shares Down 0.8%

Zolmax Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report)'s stock price traded down 0.8% during trading on Friday . The company traded as low as $2.53 and last traded at $2.55. 39,156 shares...\n more…

Comparing Nautilus Biotechnology (NASDAQ:NAUT) and Prenetics Global (NASDAQ:PRE)

Ticker Report Prenetics Global (NASDAQ:PRE - Get Free Report) and Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the...\n more…

Nautilus Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Globe Newswire SEATTLE, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or Nautilus ), a company pioneering a single-molecule proteome analysis platform, today announced the company...\n more…

NAUT Stock Earnings: Nautilus Biotechnology Beats EPS for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nNAUT stock results show that Nautilus Biotechnology beat analyst estimates for earnings per share the second quarter of 2024.\nThe post...\n more…

Nautilus Biotechnology Reports Second Quarter 2024 Financial Results

Globe Newswire SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or Nautilus ), a company pioneering a single-molecule proteome analysis platform, today reported financial...\n more…